Kenvue faces FDA petition to remove key Benadryl ingredient

Kenvue Inc. is dealing with another challenge to a top-selling product as it attempts to close its $40 billion acquisition by ...

Kenvue Inc. stock falls Thursday, underperforms market

Shares of Kenvue Inc. KVUE slid 1.04% to $17.10 Thursday, on what proved to be an all-around positive trading session for the ...

How the Narrative Surrounding Kimberly-Clark Is Shifting After the Planned Kenvue Acquisition

Kimberly-Clark's latest valuation update reflects only a slight trim to its fair value estimate, nudging it from about ...

Kimberly-Clark Reaches For Kenvue: Life-Saving Hand Or Capitalizing On Weakness?

KVUE's stock performance has suffered from legacy investor selling, management turnover, litigation risks, and a profit ...

Tylenol makers J&J, Kenvue not registered to operate in Texas, says AG Ken Paxton

"I will not allow Big Pharma to operate above the law or put their greed ahead of Texans’ well-being," said Paxton.

Kenvue: Worth Owning As Kimberly-Clark Deal Plays Out

Kimberly-Clark stock provides an interesting opportunity amid the $48.7 billion Kenvue acquisition. Learn more about KVUE and ...

4KVUE : P/E Ratio Insights for Kenvue

Kenvue has a lower P/E than the aggregate P/E of 55.57 of the Personal Products industry. Ideally, one might believe that the ...

Kenvue and J&J must register in Texas or face business ban, judge rules

A Texas judge has ordered Tylenol-maker Kenvue Inc. and its former parent Johnson & Johnson to register with the Texas Secretary of State or risk being barred from doing business in the state.
WGAL

Kimberly-Clark to acquire Tylenol maker Kenvue in $48.7 billion deal

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.Kenvue shareholders will receive $3.50 per share in ...